AR019115A1 - Derivados de la 1-[(1-sustituido-4-piperidinil)metil]-4-piperidina, procesos para la preparacion de los mismos, composiciones farmaceuticas que loscontienen y los compuestos intermedios para prepararlos - Google Patents
Derivados de la 1-[(1-sustituido-4-piperidinil)metil]-4-piperidina, procesos para la preparacion de los mismos, composiciones farmaceuticas que loscontienen y los compuestos intermedios para prepararlosInfo
- Publication number
- AR019115A1 AR019115A1 ARP990101966A ARP990101966A AR019115A1 AR 019115 A1 AR019115 A1 AR 019115A1 AR P990101966 A ARP990101966 A AR P990101966A AR P990101966 A ARP990101966 A AR P990101966A AR 019115 A1 AR019115 A1 AR 019115A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- lower alkyl
- alkyl group
- hydrogen atom
- substituted
- Prior art date
Links
- -1 1-SUBSTITUTED-4-PIPERIDINYL Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000002325 prokinetic agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se describen derivados de la 1-[(1-sustituido-4-piperidinil)metil]-4-piperidina de formula (I) y las sales farmacéuticamente aceptables de los mismos. Enla formula 1 Ar es un grupo de la formula siguiente (Ar-1) o (Ar-2): (en donde R1 es un átomo dehalogeno. R2 es un átomo de hidrogeno o un grupo alquiloinferior, R3 es un átomo de hidrogeno, un grupo alquilo inferior, o un grupo de alcanoilo inferior, R4 es un átomo de hidrogeno o un grupo de alquilo inferiory R5 y R6 son lo mismo o diferente ycada uno un átomo de hidrogeno o un grupo alquilo inferior, y n es 1, 2 o 3). A es un grupo de laformula siguiente (A-1).(A2) o (A-3: -Z-N(Q1)(Q2) (A-1) (en donde Z es -CO-, -CS- o -SO2-, Q1 y Q2 son los mismos o diferentes y cada uno un átomo dehidrogeno o un grupo de alquilo inferior, un grupo de cicloalquilo, un grupo de fenilo sustituido o no sustituido, o un grupo de alquilfenil inferior, o Q1 yQ2 pueden combinarse juntos con el átomo de nitrogeno al cual pueden enlazarse para formar un anillo de pirrolidina, un anillo de piperidina, un anillo dehexahidroazepina, un anillo de morfolina, un anillo de tiomorfolina, o un anillo de piperazina que tiene opcionalmente un alquilo inferior o un sustituyentesobre el otro átomo de nitrogeno):-CO-R7 (A-2) (en el cual R7 es un átomo de hidrogeno o un grupo de alquilo inferior, un grupo de alcoxi inferior, un grupode alcoxicarbonilo inferior, un grupo de alquilo inferior que es sustituido por un grupo de hidroxi, alcoxi inferior, o alcoxi-carbonilo inferior, o un grupode fenilo sustituido o no sustituido): -CH2)p-CH(R8)-COR9 (A-3) (en el cual p es 0, 1, 2, 3, 4 o 5 R8 es un átomo de hidrogeno o un grupo de alquilo inferior,y R9 es un grupo de alquilo o un grupo de alcoxi inferior). Sedescriben además los procesos para prepararlos, las composiciones farmacéuticas conteniendo losmismos y los compuestos intermediarios de síntesis. Los compuestos (I) muestran una actividad agonista potente sobre 4 receptores de serotonina, denominadosreceptores 5-HT4 y son utiles como reforzadores de la movilidad gastrointestinal o como agentes procinéticos gastrointestinales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13450498 | 1998-04-28 | ||
| JP19501998 | 1998-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR019115A1 true AR019115A1 (es) | 2001-12-26 |
Family
ID=26468607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101966A AR019115A1 (es) | 1998-04-28 | 1999-04-28 | Derivados de la 1-[(1-sustituido-4-piperidinil)metil]-4-piperidina, procesos para la preparacion de los mismos, composiciones farmaceuticas que loscontienen y los compuestos intermedios para prepararlos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6294555B1 (es) |
| EP (1) | EP1076055B1 (es) |
| KR (1) | KR20010043032A (es) |
| CN (1) | CN1118452C (es) |
| AR (1) | AR019115A1 (es) |
| AT (1) | ATE283260T1 (es) |
| AU (1) | AU746406B2 (es) |
| BR (1) | BR9909991A (es) |
| CA (1) | CA2330475A1 (es) |
| DE (1) | DE69922186T2 (es) |
| ES (1) | ES2234248T3 (es) |
| HK (1) | HK1031869A1 (es) |
| HU (1) | HUP0101511A3 (es) |
| ID (1) | ID26399A (es) |
| IL (1) | IL138568A0 (es) |
| NO (1) | NO318451B1 (es) |
| NZ (1) | NZ507119A (es) |
| PL (1) | PL343726A1 (es) |
| PT (1) | PT1076055E (es) |
| RU (1) | RU2214400C2 (es) |
| SK (1) | SK15852000A3 (es) |
| TW (1) | TWI242004B (es) |
| WO (1) | WO1999055674A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6344358B1 (en) * | 1999-05-28 | 2002-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| NZ530202A (en) | 2001-07-02 | 2005-06-24 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US6696468B2 (en) * | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) * | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| TW200533348A (en) * | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| US7728006B2 (en) * | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) * | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US20050267141A1 (en) * | 2004-05-28 | 2005-12-01 | Phytogen Life Sciences Inc. | Process to prepare camptothecin derivatives |
| DE602005014566D1 (de) * | 2004-11-05 | 2009-07-02 | Theravance Inc | Chinolinon-carboxamid-verbindungen |
| JP5086091B2 (ja) * | 2004-11-05 | 2012-11-28 | セラヴァンス， インコーポレーテッド | ５−ｈｔ４受容体アゴニスト化合物 |
| CN101080406A (zh) * | 2004-12-22 | 2007-11-28 | 施万制药 | 吲唑－甲酰胺化合物 |
| EP1871772B1 (en) * | 2005-03-02 | 2014-09-10 | Theravance, Inc. | Quinolinone compounds as 5-ht4 receptor agonists |
| US7256294B2 (en) * | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
| MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| JP2009501793A (ja) | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | 新規ピペリジン誘導体 |
| TWI423967B (zh) * | 2008-02-21 | 2014-01-21 | Dainippon Sumitomo Pharma Co | 醯胺衍生物及含有其之醫藥組合物 |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| DK2780015T3 (en) * | 2011-11-18 | 2017-03-27 | Heptares Therapeutics Ltd | M1 MUSCARINRECEPTORAGONISTER |
| WO2017137910A1 (en) * | 2016-02-11 | 2017-08-17 | Symed Labs Limited | Processes for the preparation of highly pure prucalopride succinate and its intermediates |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110950843B (zh) * | 2019-11-28 | 2022-12-27 | 广东东阳光药业有限公司 | 取代的苯酰胺衍生物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9005014D0 (en) | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
| GB9204565D0 (en) | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5864039A (en) | 1994-03-30 | 1999-01-26 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzoic acid compounds and use thereof as medicaments |
| WO1996033973A1 (fr) * | 1995-04-28 | 1996-10-31 | Banyu Pharmaceutical Co., Ltd. | Derives disubstitues en position 1,4 de piperidine |
| JPH111472A (ja) * | 1996-04-30 | 1999-01-06 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体及びそれを含有する医薬組成物 |
-
1999
- 1999-04-19 CN CN99805583A patent/CN1118452C/zh not_active Expired - Fee Related
- 1999-04-19 IL IL13856899A patent/IL138568A0/xx unknown
- 1999-04-19 PL PL99343726A patent/PL343726A1/xx unknown
- 1999-04-19 SK SK1585-2000A patent/SK15852000A3/sk unknown
- 1999-04-19 RU RU2000129161/04A patent/RU2214400C2/ru not_active IP Right Cessation
- 1999-04-19 HU HU0101511A patent/HUP0101511A3/hu unknown
- 1999-04-19 TW TW088106200A patent/TWI242004B/zh active
- 1999-04-19 CA CA002330475A patent/CA2330475A1/en not_active Abandoned
- 1999-04-19 PT PT99913701T patent/PT1076055E/pt unknown
- 1999-04-19 EP EP99913701A patent/EP1076055B1/en not_active Expired - Lifetime
- 1999-04-19 NZ NZ507119A patent/NZ507119A/xx unknown
- 1999-04-19 AU AU31716/99A patent/AU746406B2/en not_active Ceased
- 1999-04-19 US US09/674,162 patent/US6294555B1/en not_active Expired - Fee Related
- 1999-04-19 DE DE69922186T patent/DE69922186T2/de not_active Expired - Fee Related
- 1999-04-19 BR BR9909991-8A patent/BR9909991A/pt not_active IP Right Cessation
- 1999-04-19 ID IDW20002107A patent/ID26399A/id unknown
- 1999-04-19 AT AT99913701T patent/ATE283260T1/de not_active IP Right Cessation
- 1999-04-19 ES ES99913701T patent/ES2234248T3/es not_active Expired - Lifetime
- 1999-04-19 KR KR1020007011894A patent/KR20010043032A/ko not_active Application Discontinuation
- 1999-04-19 WO PCT/JP1999/002056 patent/WO1999055674A1/ja not_active Application Discontinuation
- 1999-04-28 AR ARP990101966A patent/AR019115A1/es unknown
-
2000
- 2000-10-27 NO NO20005430A patent/NO318451B1/no unknown
-
2001
- 2001-03-28 HK HK01102252A patent/HK1031869A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US6294555B1 (en) | 2001-09-25 |
| TWI242004B (en) | 2005-10-21 |
| HUP0101511A3 (en) | 2002-12-28 |
| WO1999055674A1 (fr) | 1999-11-04 |
| DE69922186T2 (de) | 2005-05-04 |
| EP1076055B1 (en) | 2004-11-24 |
| NZ507119A (en) | 2002-08-28 |
| EP1076055A1 (en) | 2001-02-14 |
| HK1031869A1 (en) | 2001-06-29 |
| HUP0101511A2 (hu) | 2001-09-28 |
| AU3171699A (en) | 1999-11-16 |
| SK15852000A3 (sk) | 2001-06-11 |
| PL343726A1 (en) | 2001-09-10 |
| PT1076055E (pt) | 2005-02-28 |
| NO318451B1 (no) | 2005-03-21 |
| AU746406B2 (en) | 2002-05-02 |
| IL138568A0 (en) | 2001-10-31 |
| CN1118452C (zh) | 2003-08-20 |
| KR20010043032A (ko) | 2001-05-25 |
| ES2234248T3 (es) | 2005-06-16 |
| CA2330475A1 (en) | 1999-11-04 |
| DE69922186D1 (de) | 2004-12-30 |
| EP1076055A4 (en) | 2001-07-18 |
| NO20005430L (no) | 2000-12-20 |
| NO20005430D0 (no) | 2000-10-27 |
| BR9909991A (pt) | 2000-12-26 |
| ATE283260T1 (de) | 2004-12-15 |
| RU2214400C2 (ru) | 2003-10-20 |
| ID26399A (id) | 2000-12-21 |
| CN1298391A (zh) | 2001-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR019115A1 (es) | Derivados de la 1-[(1-sustituido-4-piperidinil)metil]-4-piperidina, procesos para la preparacion de los mismos, composiciones farmaceuticas que loscontienen y los compuestos intermedios para prepararlos | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| PA8490601A1 (es) | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos. | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR069271A1 (es) | Dihidrobenzo(1, 4)dioxinas sustituidas, una composicion farmaceutica que las comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por el antagonismo de alfa2c. | |
| HUP0402508A2 (hu) | 1,2,3,4-Tetrahidro-izokinolin-származékok mint urotenzin II receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| PE20061144A1 (es) | DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs) | |
| PE20021004A1 (es) | Derivados de piperidina como inhibidores de la ccr5 | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
| AR041395A1 (es) | Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| MXPA05007341A (es) | Derivados de 2-piperidona como agonistas de prostaglandina. | |
| AR041246A1 (es) | Derivados de piridina; un procedimiento de preparacion de los mismos y composicion farmaceutica que los contiene | |
| AR027539A1 (es) | Nuevos derivados de 1,3-dihidro-2h-indol-2-ona, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| AR033942A1 (es) | Compuestos de monofluoroalquilo aplicables en la potenciacion de los compuestos intermediarios utilizables en la sintesis de dichos compuestos de monofluoralquilo; composiciones farmaceuticas formuladas con dichos compuestos potenciadores y metodos para la potenciacion de las funciones de dichos rec | |
| PE20040578A1 (es) | Derivados de 1-[(indol-3-il)carbonil]piperazina | |
| PE20050231A1 (es) | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 | |
| CO5660263A2 (es) | Derivados de imidazol heteroaril sustituidos como antagonistas del receptor de glutamato | |
| MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR054072A1 (es) | 3-amino arilpropil indoles como inhibidores de reabsorcion de monoaminas. procesos de obtencion y composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |